Boland. Sinopsis de psiquiatría_12ed

364

Kaplan & Sadock. Sinopsis de psiquiatría

Moreno-Küstner B, Martín C, Pastor L. Prevalence of psychotic disorders and its asso- ciation with methodological issues. A systematic review and meta-analyses. PLoS One . 2018;13(4):e0195687. Morrison AP, Turkington D, Pyle M, Spencer H, Brabban A, Dunn G, Christodoulides T, Dudley R, Chapman N, Callcott P, Grace T, Lumley V, Drage L, Tully S, Irving K, Cummings A, Byrne R, Davies LM, Hutton P. Cognitive therapy for people with schizophrenia spectrum disorders not taking antipsychotic drugs: A single-blind randomised controlled trial. Lancet . 2014;383(9926):1395–1403. National Collaborating Centre for Mental Health (UK). Psychosis and Schizophrenia in Adults: Treatment and Management: Updated Edition 2014; 2014. Available at http://www.ncbi.nlm.nih.gov/books/NBK248060/ Orfanos S, Banks C, Priebe S. Are group psychotherapeutic treatments effective for patients with schizophrenia? A systematic review and meta-analysis. Psychother Psychosom . 2015;84(4):241–249. Overall JE, Gorham DR. The Brief Psychiatric Rating Scale (BPRS): Recent deve- lopments in ascertainment and scaling. Psychopharmacol Bull . 1988;24(1):97–99. Pharoah F, Mari J, Rathbone J, Wong W. Family intervention for schizophrenia. Cochrane Database Syst Rev . 2010;(12):CD000088. Poloni N, Ielmini M, Caselli I, Lucca G, Gasparini A, Gasparini A, Lorenzoli G, Callegari C. Oral antipsychotic versus long-acting injections antipsychotic in schi- zophrenia spectrum disorder: A mirror analysis in a real-world clinical setting. Psychopharmacol Bull . 2019;49(2):17–27. Samara MT, Leucht C, Leeflang MM, Anghelescu IG, Chung YC, Crespo-Facorro B, Elkis H, Hatta K, Giegling I, Kane JM, Kayo M, Lambert M, Lin CH, Möller HJ, Pelayo-Terán JM, Riedel M, Rujescu D, Schimmelmann BG, Serretti A, Correll CU, Leucht S. Early improvement as a predictor of later response to antipsychotics in schizophrenia: A diagnostic test review. Am J Psychiatry . 2015;172(7):617–629. Sampson S, Mansour M, Maayan N, Soares-Weiser K, Adams CE. Intermittent drug techniques for schizophrenia. Cochrane Database Syst Rev . 2013;(7):CD006196. Schizophrenia Working Group of the Psychiatric Genomics Consortium. Biological insights from 108 schizophrenia-associated genetic loci. Nature . 2014;511(7510): 421–427. Sekar A, Bialas AR, de Rivera H, Davis A, Hammond TR, Kamitaki N, Tooley K, Presumey J, Baum M, Van Doren V, Genovese G, Rose SA, Handsaker RE; Schi- zophrenia Working Group of the Psychiatric Genomics Consortium, Daly MJ, Carroll MC, Stevens B, McCarroll SA. Schizophrenia risk from complex variation of complement component 4. Nature . 2016;530(7589):177–183. Simpson GM, Angus JW. A rating scale for extrapyramidal side effects. Acta Psychiatr Scand Suppl . 1970;212:11–19. Tomasik J, Rahmoune H, Guest PC, Bahn S. Neuroimmune biomarkers in schizophre- nia. Schizophr Res . 2016;176(1):3–13. Volkow ND. Substance use disorders in schizophrenia—Clinical implications of comorbidity. Schizophr Bull . 2009;35(3):469–472. Walsh T, McClellan JM, McCarthy SE, Addington AM, Pierce SB, Cooper GM, Nord AS, Kusenda M, Malhotra D, Bhandari A, Stray SM, Rippey CF, Roccanova P, Makarov V, Lakshmi B, Findling RL, Sikich L, Stromberg T, Merriman B, Gogtay N, Butler P, Eckstrand K, Noory L, Gochman P, Long R, Chen Z, Davis S, Baker C, Eichler EE, Meltzer PS, Nelson SF, Singleton AB, Lee MK, Rapoport JL, King MC, Sebat J. Rare structural variants disrupt multiple genes in neurodevelopmental pathways in schizophrenia. Science . 2008;320(5875):539–543. Weinberger DR. Future of days past: Neurodevelopment and schizophrenia. Schizophr Bull . 2017;43(6):1164–1168. Wójciak P, Rybakowski J. Clinical picture, pathogenesis and psychometric assessment of negative symptoms of schizophrenia. Psychiatr Pol . 2018;52(2):185–197. Zareifopoulos N, Bellou A, Spiropoulou A, Spiropoulos K. Prevalence of comorbid chronic obstructive pulmonary disease in individuals suffering from schizophrenia and bipolar disorder: A systematic review. COPD . 2018;15(6):612–620. Zhuo C, Hou W, Li G, Mao F, Li S, Lin X, Jiang D, Xu Y, Tian H, Wang W, Cheng L. The genomics of schizophrenia: Shortcomings and solutions. Prog Neuropsy- chopharmacol Biol Psychiatry . 2019;93:71–76.

DiLalla LF, McCrary M, Diaz E. A review of endophenotypes in schizophrenia and autism: The next phase for understanding genetic etiologies. Am J Med Genet C Semin Med Genet . 2017;175(3):354–361. Fischer M. Psychoses in the offspring of schizophrenic monozygotic twins and their normal co-twins. Br J Psychiatry . 1971;118(542):43–52. Furukawa TA, Levine SZ, Tanaka S, GoldbergY, Samara M, Davis JM, Cipriani A, Leucht S. Initial severity of schizophrenia and efficacy of antipsychotics: Participant-level meta-analysis of 6 placebo-controlled studies. JAMA Psychiatry . 2015;72(1):14–21. GuyW. ECDEUAssessment Manual for Psychopharmacology (Rev. 1976.) . Rockville, MD: U.S. Dept. of Health, Education, and Welfare, Public Health Service, Alcohol, Drug Abuse, and Mental Health Administration, National Institute of Mental Health, Psychopharmacology Research Branch, Division of Extramural Research Programs; 1976. Jones C, Hacker D, Cormac I, Meaden A, Irving CB, Xia J, Shi C, Chen J. Cognitive behavioral therapy plus standard care versus standard care plus other psychosocial treatments for people with schizophrenia. Schizophr Bull . 2019;45(2):284–286. Jones P, Rodgers B, Murray R, Marmot M. Child development risk factors for adult schizophrenia in the British 1946 birth cohort. Lancet . 1994;344(8934): 1398–1402. Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull . 1987;13(2):261–276. Kendell RE, Cooper JE, Gourlay AJ, Copeland JR, Sharpe L, Gurland BJ. Diagnos- tic criteria of American and British psychiatrists. Arch Gen Psychiatry . 1971;25(2): 123–130. Kesby J, Eyles D, McGrath J, Scott J. Dopamine, psychosis and schizophrenia: The widening gap between basic and clinical neuroscience. Transl Psychiatry . 2018;8(1):30. Khokhar JY, Dwiel LL, Henricks AM, Doucette WT, Green AI. The link between schizophrenia and substance use disorder: A unifying hypothesis. Schizophr Res . 2018;194:78–85. Kirson NY, Weiden PJ, Yermakov S, Huang W, Samuelson T, Offord SJ, Greenberg PE, Wong BJO. Efficacy and effectiveness of depot versus oral antipsychotics in schi- zophrenia: Synthesizing results across different research designs. J Clin Psychiatry . 2013;74(6):568–575. Kishimoto T, Robenzadeh A, Leucht C, Leucht S, Watanabe K, Mimura M, Borenstein M, Kane JM, Correll CU. Long-acting injectable vs oral antipsychotics for relapse prevention in schizophrenia: A meta-analysis of randomized trials. Schizophr Bull . 2014;40(1):192–213. Kondej M, Ste pnicki P, Kaczor AA. Multi-target approach for drug discovery against schizophrenia. Int J Mol Sci . 2018;19(10):3105. Kumari V, Das M, Zachariah E, Ettinger U, Sharma T. Reduced prepulse inhibition in unaffected siblings of schizophrenia patients. Psychophysiology . 2005;42(5): 588–594. Leucht C, Heres S, Kane JM, Kissling W, Davis JM, Leucht S. Oral versus depot antipsychotic drugs for schizophrenia—A critical systematic review and meta-analy- sis of randomised long-term trials. Schizophr Res . 2011;127(1–3):83–92. Leucht S, Cipriani A, Spineli L, Mavridis D, Orey D, Richter F, Samara M, Barbui C, Engel RR, Geddes JR, Kissling W, Stapf MP, Lässig B, Salanti G, Davis JM. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: A multiple-treatments meta-analysis. Lancet . 2013;382(9896):951–962. Lieberman JA, First MB. Psychotic disorders. N Engl J Med . 2018;379(3):270–280. Malavia TA, Chaparala S, Wood J, Chowdari K, Prasad KM, McClain L, Jegga AG, Ganapathiraju MK, Nimgaonkar VL. Generating testable hypotheses for schizophre- nia and rheumatoid arthritis pathogenesis by integrating epidemiological, genomic, and protein interaction data. NPJ Schizophr . 2017;3:11. McCutcheon RA, Abi-DarghamA, Howes OD. Schizophrenia, dopamine and the stria- tum: From biology to symptoms. Trends Neurosci . 2019;42(3):205–220.

Mirsky AF, Silberman EK, Latz A, Nagler S. Adult outcomes of high-risk children: Differential effects of town and kibbutz rearing. Schizophr Bull . 1985;11(1): 150–154. SAMPLE